Last reviewed · How we verify
gemcitabine, S-1, radiotherapy
At a glance
| Generic name | gemcitabine, S-1, radiotherapy |
|---|---|
| Also known as | gemzer, TS-1 |
| Sponsor | Osaka Medical Center for Cancer and Cardiovascular Diseases |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Metastasis-directed Therapy for Oligometastases of Breast Cancer (PHASE3)
- A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma (PHASE2)
- SBRT Combined With Nimotuzumab and Mono-chemotherapy in Locally Advanced Pancreatic Cancer (PHASE2)
- Borderline Resectable Pancreatic Cancer Neoadjuvant Chemoradiotherapy Clinicaltrial-1 (PHASE2)
- Sufficient Chemotherapy Combine With Maintenance Chemotherapy in the Treatment of Oligometastatic Nasopharyngeal Carcinoma (PHASE2)
- Chemoradiotherapy With Gemcitabine/S-1 vs Gemcitabine/S-1 for Locally Advanced Pancreatic Cancer (PHASE2)
- IORT Followed by CCRT or SBRT for Locally Advanced Pancreatic Cancer (NA)
- Phase I Study of TS-1 With Concurrent Radiotherapy to Treat Pancreatic Cancer (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: